DGX Earnings Date: Feb 9, 2027 (Estimated) — Quest Diagnostics Incorporated
NYSE · Healthcare · Diagnostics & Research
Updated
When is DGX's next earnings date?
Quest Diagnostics Incorporated (DGX) is expected to report Q4 2026 earnings on Tuesday, February 9, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.68 on revenue of $3.01B.
How did DGX do in its last earnings report?
In its most recent report on Oct 22, 2026 (Q3 2026), Quest Diagnostics Incorporated posted EPS of $3.00 versus the $2.87 estimate, a beat of 4.5%. Revenue was $3.10B against a $3.04B estimate. The stock's 1-day post-earnings move was +1.8%.
How much does DGX stock move after earnings?
DGX beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
🤖 AI Earnings Analysis
Quest Diagnostics delivered a strong Q3 beat, with revenue up 11% to $3.1B and EPS rising 15% to $3.00; diagnostics demand appears resilient. Full-year guidance targets $11.05–$11.25 EPS and $11.9B–$12.1B revenue.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-22 | Q3 2026 | 2.87 | 3.00 | +4.53% | $3.10B | ✅ Beat | +1.82% | +2.80% | — |
| 2026-07-23 | Q2 2026 | 2.82 | 3.12 | +10.64% | $3.04B | ✅ Beat | +8.62% | +12.10% | +15.00% |
| 2026-04-21 | Q1 2026 | 2.36 | 2.50 | +5.93% | $2.90B | ✅ Beat | +4.44% | +0.16% | -3.02% |
| 2026-02-10 | Q4 2025 | 2.35 | 2.42 | +2.98% | $2.81B | ✅ Beat | +7.37% | +7.45% | +4.87% |
| 2025-10-21 | Q3 2025 | 2.51 | 2.60 | +3.59% | $2.82B | ✅ Beat | -3.03% | -5.33% | -2.68% |
| 2025-04-22 | Q1 2025 | 2.15 | 2.21 | +2.79% | $2.65B | ✅ Beat | +6.78% | +9.16% | +10.12% |
| 2025-01-30 | Q4 2024 | 2.18 | 2.23 | +2.29% | $2.62B | ✅ Beat | +5.62% | +6.07% | +11.23% |
| 2024-10-22 | Q3 2024 | 2.26 | 2.30 | +1.77% | $2.49B | ✅ Beat | +6.86% | +5.81% | +9.36% |
Showing last 8 quarters.